Cameron E Snell
Overview
Explore the profile of Cameron E Snell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gough M, Kwah K, Khan T, Ghosh S, Sun B, Lee C, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39869307
Purpose: Receptor CUB-domain containing- protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer. Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423...
2.
Gough M, Liu C, Srinivasan B, Wilkinson L, Dunk L, Yang Y, et al.
Histopathology
. 2023 Jun;
83(4):647-656.
PMID: 37366040
Aims: Accurate assessment of human epidermal growth factor receptor 2 (HER2) expression by HER2 immunohistochemistry and in-situ hybridisation (ISH) is critical for the management of patients with breast cancer. The...
3.
Khan T, Lyons N, Gough M, Kwah K, Cuda T, Snell C, et al.
Theranostics
. 2022 Oct;
12(16):6915-6930.
PMID: 36276654
An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are...
4.
Sengal A, Smith D, Snell C, Leung S, Talhouk A, Williams E, et al.
J Pathol Clin Res
. 2022 Jul;
8(6):521-537.
PMID: 35866380
Endometrial carcinoma (EC) is the most common gynecological malignancy and fibroblast growth factor receptor 2 (FGFR2) is a frequently dysregulated receptor tyrosine kinase. FGFR2b and FGFR2c are the two main...
5.
Cuda T, He Y, Kryza T, Khan T, Tse B, Sokolowski K, et al.
Contrast Media Mol Imaging
. 2021 Oct;
2021:3153278.
PMID: 34621145
Colorectal cancer (CRC) is the third most common malignancy in the world, with 22% of patients presenting with metastatic disease and a further 50% destined to develop metastasis. Molecular imaging...
6.
Keshvari S, Caruso M, Teakle N, Batoon L, Sehgal A, Patkar O, et al.
PLoS Genet
. 2021 Jun;
17(6):e1009605.
PMID: 34081701
Homozygous mutation of the Csf1r locus (Csf1rko) in mice, rats and humans leads to multiple postnatal developmental abnormalities. To enable analysis of the mechanisms underlying the phenotypic impacts of Csf1r...
7.
Sengal A, Smith D, Rogers R, Snell C, Williams E, Pollock P
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33916719
Women with atypical hyperplasia (AH) or well-differentiated early-stage endometrioid endometrial carcinoma (EEC) who wish to retain fertility and/or with comorbidities precluding surgery, are treated with progestin. Clinically approved predictive biomarkers...
8.
Huang X, Reye G, Momot K, Blick T, Lloyd T, Tilley W, et al.
Front Cell Dev Biol
. 2021 Apr;
9:678589.
PMID: 33869234
[This corrects the article DOI: 10.3389/fcell.2020.00599.].
9.
Wafai R, Williams E, de Souza E, Simpson P, McCart Reed A, Kutasovic J, et al.
Breast Cancer Res
. 2020 Dec;
22(1):136.
PMID: 33276802
Background: Breast cancers acquire aggressive capabilities via epithelial to mesenchymal transition (EMT), in which various integrins/integrin-linked kinase signalling are upregulated. Methods: We investigated this in two patient-derived xenografts (PDXs) developed...
10.
Huang X, Reye G, Momot K, Blick T, Lloyd T, Tilley W, et al.
Front Cell Dev Biol
. 2020 Aug;
8:599.
PMID: 32760722
Mammographic density (MD) is a strong and independent factor for breast cancer (BC) risk and is increasingly associated with BC progression. We have previously shown in mice that high MD,...